Media about us

• Pfizer Inc. (PFE) Ready to Reconnoiter Russian Therapeutic Markets

  18 July 2016 Raheel Farooq / Business Finance News

  

  As restrictions in the Western countries rise and growth remains stagnant, Pfizer has taken a wise step to slowly and steadily enter Russia with the establishment of a manufacturing unit. Pfizer Inc. is in the process to develop manufacturing facilities in numerous geographical territories around the globe. Recently, the drug maker signed its third mega deal in the past several years, which is an agreement with Russia’s NovaMedica to build a manufacturing unit.

• Pfizer strikes second deal this year for drug production in Russia

  18 July 2016 Eric Palmer / Fierce Pharma

  

  Pfizer was a little behind some of its peers in establishing local manufacturing in Russia but it's on a roll now, having just announced its third deal in several years. It is hammering out an agreement with Russia’s NovaMedica for a new manufacturing plant. 

• Atlas Genetics mandates UBS for up to USD 30m raise — source

  15 July 2016 Mergermarket

  

  Atlas Genetics (AG), a UK-based, PE-backed point-of-care (POC) diagnostics company, is looking to raise up to USD 30m to fund clinical trials and commercialization, a source familiar with the situation said. The company has developed ultra-rapid, low cost, multiple analyte detection technology for POC use to screen the presence of sexually transmitted infections (STIs) and hospital acquired infections (HAIs).

• Pfizer's Russia Deal Shows Country Still Open To Western Business

  15 July 2016 Kenneth Rapoza / Forbes

  

  U.S. multinational drug maker Pfizer PFE +1.68% is laying down a new foundation in Russia, with a joint venture announced on Wednesday to produce pharmaceuticals domestically.

• Pfizer links with NovaMedica to produce and market drugs in Russia

  15 July 2016 The Pharma Letter

  

  US pharma giant Pfizer (NYSE: PFE) and NovaMedica, a company established by Russian high-technology investment fund Rusnano and American venture health care fund Domain Associates in 2012, have entered into an agreement to cooperate, signalling the development of a new partnership, to bring important medicines to the Russian market.

• Photo: Pfizer and NovaMedica announce a strategic partnership in Russia

  13 July 2016

  

  Pfizer, one of the world’s premier biopharmaceutical companies and NovaMedica, a Russian pharmaceutical company established by Rusnano and Domain Associates, have entered into an agreement to cooperate, signalling the development of a new partnership. Through this partnership, Pfizer proposes to invest in NovaMedica’s construction of a new manufacturing plant in the Kaluga region and license the technology for production of more than 30 medicinal products from its portfolio to the Russian partner.

• EyewireTV – FDA Approves Raindrop Inlay; Humira for Uveitis Treatment

  08 July 2016 EyeWire Today

  

  In this week’s EyewireTV, ReVision Optics receives FDA approval for the Raindrop Near Vision Inlay, the first implantable device that changes the shape of the cornea to achieve improved vision; and the FDA approves Humira (adalimumab) for the treatment of noninfectious intermediate and posterior uveitis and panuveitis. Also, Bausch + Lomb and Nicox announce that the results of a phase 3 study of glaucoma drug candidate latanoprostene bunod have been published in the American Journal of Ophthalmology.

• Test Aids Prostate Cancer Treatment

  07 July 2016 Ron Winslow / The Wall Street Journal

  

  Genomic Health Inc. has struck a deal to commercialize a new blood test that can help advanced prostate cancer patients decide whether to try costly new-generation drugs or rely on much cheaper traditional chemotherapy to improve their chances for survival. The test, developed by closely held Epic Sciences Inc., San Diego, detects a mutation associated with a poor response to two new drugs, Xtandi from Medivation Inc. and Astellas Pharma Inc. of Japan, and Zytiga from Johnson & Johnson.

• New blood test from Epic Sciences matches patients with PARP inhibitors

  30 June 2016 Josh Baxt / MedCityNews

  

  San Diego-based liquid biopsy company Epic Sciences has announced a new blood test that may quickly identify cancer patients who respond to a promising class of drugs called poly ADP ribose polymerase (PARP) inhibitors. The test works by identifying circulating tumor cells (CTCs) affected by homologous recombination deficiency (HRD), a damaged DNA repair mechanism.

• Epic Sciences unveils new, more sensitive biopsy test to detect a range of cancers

  28 June 2016 Joseph Keenan / Fierce Medical Devices

  

  San Diego's Epic Sciences has added a new liquid biopsy test to its arsenal of biopharma cancer detection tools that targets homologous recombination deficiencies (HRDs) in individual circulating tumor cells.